| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236799 | ALMIRALL | Biaryl compositions and methods for modulating a kinase cascade |
Dec, 2025
(1 year, 8 months from now) | |
| US8980890 | ALMIRALL | Compositions and methods of treating cell proliferation disorders |
Dec, 2025
(1 year, 8 months from now) | |
| US7300931 | ALMIRALL | Compositions for treating cell proliferation disorders |
Feb, 2026
(1 year, 9 months from now) | |
| US7851470 | ALMIRALL | Composition and methods for modulating a kinase cascade |
Feb, 2029
(4 years from now) | |
| US10669236 | ALMIRALL | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide |
Sep, 2038
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10323001 | ALMIRALL | Compositions for modulating a kinase cascade and methods of use thereof |
Dec, 2027
(3 years from now) | |
| US10617693 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(13 years from now) | |
| US11497750 | ALMIRALL | Methods of treating and/or preventing actinic keratosis |
Mar, 2038
(13 years from now) | |
Klisyri is owned by Almirall.
Klisyri contains Tirbanibulin.
Klisyri has a total of 8 drug patents out of which 0 drug patents have expired.
Klisyri was authorised for market use on 14 December, 2020.
Klisyri is available in ointment;topical dosage forms.
Klisyri can be used as topical treatment of actinic keratosis of the face or scalp.
Drug patent challenges can be filed against Klisyri from 14 December, 2024.
The generics of Klisyri are possible to be released after 07 September, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2025 |
Drugs and Companies using TIRBANIBULIN ingredient
NCE-1 date: 14 December, 2024
Market Authorisation Date: 14 December, 2020
Treatment: Topical treatment of actinic keratosis of the face or scalp
Dosage: OINTMENT;TOPICAL
KLISYRI family patents
